Chicago, IL –September 13, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: ExxonMobil XOM, Chevron CVX, BP plc BP, Royal Dutch Shell RDS.A and Valero Energy VLO.
Here are highlights from Thursday’s Analyst Blog:
U.S. Oil Goes Lower Even After Drop in Inventories
Oil finished lower on Wednesday even as a U.S. government report revealed a weekly decrease in domestic crude supplies that was much larger than anticipated. While EIA reported a fourth straight weekly inventory decline, crude prices fell $1.65 (or 2.9%) to $55.75 a barrel, after OPEC cut its forecast for oil demand growth this year and next. Reports that President Donald Trump may soften his stance against Iran resulted in further downside.
Most energy stocks posted losses in reaction to oil’s descent yesterday. Among the supermajors, ExxonMobil shares fell 0.2%, Chevron retreated 0.5%, BP plc was down 0.1%, while Royal Dutch Shell fell 0.6%.
Analysis of the EIA Data
Crude Oil:The federal government’s EIA report revealed that crude inventories fell by 6.9 million barrels for the week ending Sep 6, compared with the 3.6 million barrels drawdown that energy analysts had expected. A combination of lower imports and higher refinery runs largely drove the larger-than-expected stockpile decline with the world's biggest oil consumer. This puts the total domestic stocks at 416.1 million barrels – 5% above the year-ago figure and 2% lower than the five-year average.
In particular, the Cushing terminal in Oklahoma – the key delivery hub for U.S. crude futures traded on the New York Mercantile Exchange – saw inventories decline 798,000 barrels to 39.3 million barrels – the lowest since November.
The crude supply cover was down from 24.2 days in the previous week to 23.8 days. In the year-ago period, the supply cover was 22.3 days.
Turning to products, and it is a fairly bearish story.
Gasoline:Gasoline supplies edged down 682,000 barrels as demand for the fuel increased by 336,000 barrels per day to 9.8 million barrels per day. Analysts had forecast 1.4 million barrels decline. At 228.9 million barrels, the current stock of the most widely used petroleum product is 3% below the year-earlier level but exceeds the five-year average range by 3%.
Distillate:Distillate fuel supplies (including diesel and heating oil) were up 2.7 million barrels last week on lower demand and higher production, while analysts were looking for an inventory addition of 220,000 barrels. Current supplies – at 136.2 million barrels – are 2.2% lower than the year-ago level and remain 6% below than the five-year average.
Refinery Rates:Refinery utilization was up 0.3% from the prior week to 95.1%.
About the Weekly Petroleum Status Report
The Energy Information Administration (EIA) Petroleum Status Report, containing data of the previous week ending Friday, outlines information regarding the weekly change in petroleum inventories held and produced by the U.S., both locally and abroad.
The report provides an overview of the level of reserves and their movements, thereby helping investors understand the demand/supply dynamics of petroleum products. It is an indicator of current oil prices and volatility that affect the businesses of the companies engaged in the oil and refining industry.
The data from EIA generally acts as a catalyst for crude prices and affect producers, such as ExxonMobil and Chevron -- carrying a Zacks Rank #3 (Hold) – and refiners such as Valero Energy.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
